HOUSTON / May 03, 2023 / Business Wire / U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention (“IIP”) services, today reported results for the three months ended March 31, 2023 (“2023 First Quarter”).
FIRST QUARTER RESULTS SUMMARY
MANAGEMENT’S COMMENTS
Chris Reading, Chief Executive Officer, said, “I am supremely proud of our team for the way they have focused on making a difference for our patients as well as our business. The inflationary environment in the second half of 2022 was extremely challenging, but our partners, staff, leadership, and support teams remained committed to making the necessary adjustments, allowing us to deliver record volumes in what is normally a slower quarter. Our staffing has improved markedly, and our turnover rate has continued to decline to better than pre-pandemic levels for licensed clinical staff. Development activity and related opportunities remain strong.”
Carey Hendrickson, Chief Financial Officer, said, “Our outstanding physical therapy volume in the first quarter, which is typically our seasonally lowest volume quarter of the year, combined with stabilizing expenses, resulted in the best Operating Results and Adjusted EBITDA for a first quarter in our history. Our physical therapy operating costs per visit declined in the first quarter from the higher levels we experienced in the third and fourth quarters of 2022 when we began to feel the effects of inflation, and were actually lower than in the first quarter of the prior year resulting in margin improvement year over year.”
FIRST QUARTER RESULTS
Total net revenue for 2023 First Quarter was $148.5 million, an increase of 12.8%, compared to $131.7 million for the 2022 First Quarter. See table below for a breakdown of total net revenue.
Three Months Ended March 31, |
| Variance |
| ||||||||||||
| 2023 |
|
|
| 2022 |
|
| $ |
| % | |||||
Revenue related to: | (In thousands, except percentages) | ||||||||||||||
Mature clinics (1) | $ | 114,502 | $ | 108,229 | $ | 6,273 |
| 5.8 | % | ||||||
2023 clinic additions |
| 371 |
|
| - |
|
| 371 |
| * | (2) | ||||
2022 clinic additions |
| 11,708 |
|
| 195 |
|
| 11,513 |
| * | (2) | ||||
Clinics sold or closed in 2022 |
| - |
|
| 1,114 |
|
| (1,114 | ) | * | (2) | ||||
Net patient revenue from physical therapy operations |
| 126,581 |
|
| 109,538 |
|
| 17,043 |
| 15.6 | % | ||||
Other revenue |
| 799 |
|
| 872 |
|
| (73 | ) | -8.4 | % | ||||
Physical therapy operations |
| 127,380 |
|
| 110,410 |
|
| 16,970 |
| 15.4 | % | ||||
Management contracts |
| 1,779 |
|
| 2,226 |
|
| (447 | ) | -20.1 | % | ||||
IIP services |
| 19,350 |
|
| 19,068 |
|
| 282 |
| 1.5 | % | ||||
Net revenue | $ | 148,509 |
| $ | 131,704 |
| $ | 16,805 |
| 12.8 | % |
___________________________ | |
(1) | See Glossary of Terms - Revenue Metrics for the definition. |
(2) | Not meaningful. |
Operating cost was $117.7 million for the 2023 First Quarter, or 79.2% of net revenue, compared to $105.1 million, or 79.8% of net revenue, for the 2022 First Quarter. Salaries and related costs were 57.9% of net revenue for the 2023 First Quarter versus 57.1% for the 2022 First Quarter. Rent, supplies, contract labor and other costs as a percentage of total revenue were 20.3% for the 2023 First Quarter versus 21.8% for the 2022 First Quarter. The provision for credit losses as a percentage of total revenue was 1.0% for both 2023 First Quarter and 2022 First Quarter. See table below for a more detailed breakdown of operating costs.
Three Months Ended March 31, |
| Variance | |||||||||||||
| 2023 |
|
|
| 2022 |
|
| $ |
| % | |||||
| (In thousands, except percentages) |
| |||||||||||||
Operating costs related to: |
|
|
|
|
|
|
| ||||||||
Mature clinics (1) | $ | 91,025 | $ | 86,978 | $ | 4,047 |
|
| 4.7 | % | |||||
2023 clinic additions |
| 432 |
|
|
| - |
|
|
| 432 |
|
| * | (2) | |
2022 clinic additions |
| 9,100 |
|
|
| 389 |
|
| 8,711 |
|
| * | (2) | ||
Clinics sold or closed in 2022 |
| 64 |
|
|
| 1,002 |
|
|
| (940 | ) |
| * | (2) | |
Physical therapy operations |
| 100,621 |
|
|
| 88,369 |
|
|
| 12,252 |
|
| 13.9 | % | |
Management contracts |
| 1,449 |
|
|
| 1,831 |
|
|
| (382 | ) |
| -20.9 | % | |
Industrial injury prevention services |
| 15,582 |
|
|
| 14,916 |
|
|
| 666 |
|
| 4.5 | % | |
Operating costs | $ | 117,652 |
|
| $ | 105,116 |
|
| $ | 12,536 |
|
| 11.9 | % |
___________________________ | |
(1) | See Glossary of Terms - Revenue Metrics for the definition. |
(2) | Not meaningful. |
Gross profit for the 2023 First Quarter increased $4.3 million, or 16.1%, to $30.9 million from $26.6 million for the 2022 First Quarter. Gross profit margin increased to 20.8% in the 2023 First Quarter from 20.2% in the 2022 First Quarter. The following table provides a more detailed breakdown of gross profit and related gross profit margins:
Three Months Ended March 31, |
|
|
|
| ||||||||||||||||
2023 |
| 2022 |
| Variance | ||||||||||||||||
| In USD |
| Margin % |
| In USD |
| Margin % |
| $ |
| % | |||||||||
| (In thousands, except percentages) | |||||||||||||||||||
Physical therapy operations | $ | 26,759 | ) |
| 21.0 | % |
| $ | 22,041 | ) |
| 20.0 | % |
| $ | 4,718 |
|
| 21.4 | % |
Management contracts |
| 330 |
|
| 18.5 | % |
|
| 395 |
|
| 17.7 | % |
| (65 | ) |
| -16.5 | % | |
Industrial injury prevention services |
| 3,768 |
|
| 19.5 | % |
|
| 4,152 |
|
| 21.8 | % |
|
| (384 | ) |
| -9.2 | % |
Gross profit | $ | 30,857 |
|
| 20.8 | % |
| $ | 26,588 |
|
| 20.2 | % |
| $ | 4,269 |
|
| 16.1 | % |
Corporate office costs were $13.9 million, or 9.3% of net revenue, for the 2023 First Quarter compared to $11.6 million, or 8.8% of net revenue, for the 2022 First Quarter.
Operating income increased $2.0 million, or 13.1%, to $17.0 million for the 2023 First Quarter from $15.0 million in the 2022 First Quarter. In both comparative periods, the operating income was 11.4% of net revenue.
For 2023 First Quarter, other expenses were $2.6 million compared to other income of $0.4 million in 2022 First Quarter.
The provision for income tax was $3.0 million for the 2023 First Quarter compared to $3.5 million for the 2022 First Quarter. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest (effective tax rate) was 28.6% for the 2023 First Quarter and 28.4% for the 2022 First Quarter. A reconciliation of our income tax expense and effective income tax rate is as follows:
Three Months Ended March 31, | |||||||
| 2023 |
|
|
| 2022 |
| |
(In thousands, except percentages) | |||||||
|
| ||||||
Income before taxes | $ | 14,396 |
| $ | 15,480 |
| |
Less: net loss (income) attributable to non-controlling interest: | |||||||
Redeemable non-controlling interest - temporary equity |
| (2,720 | ) |
| (2,557 | ) | |
Non-controlling interest - permanent equity |
| (1,297 | ) |
| (626 | ) | |
$ | (4,017 | ) | $ | (3,183 | ) | ||
Income before taxes less net income attributable to non-controlling interest | $ | 10,379 |
| $ | 12,297 |
| |
Provision for income taxes | $ | 2,969 |
| $ | 3,498 |
| |
Effective income tax rate |
| 28.6 | % |
| 28.4 | % |
Net income attributable to redeemable non-controlling interest (temporary equity) was $2.7 million for the 2023 First Quarter and $2.6 million for the 2022 First Quarter. Net income attributable to non-controlling interest (permanent equity) was $1.3 million for the 2023 First Quarter and $0.6 million for the 2022 First Quarter.
Adjusted EBITDA, a non-GAAP measure, increased $1.0 million to $18.5 million for the 2023 First Quarter, an all-time high first quarter amount, from $17.5 million for the 2022 First Quarter.
Operating Results, excluding Relief Funds, a non-GAAP measure, was $7.7 million, or $0.59 per share, in 2023 First Quarter as compared to $8.4 million, or $0.65 per share, in 2022 First Quarter, with the decrease primarily due to the increase in interest expense previously described.
BALANCE SHEET AND CASH FLOW
As of March 31, 2023, the Company had $32.6 million in cash and cash equivalents, total net working capital of $27.0 million and $137.0 million in available credit under the Company’s Revolving Facility. During the 2023 First Quarter, $11.3 million of cash was provided by operations. The major uses of cash for investing and financing activities included: purchase of majority interest in businesses (5.8 million), purchase of non-controlling interests from existing partners ($5.2 million), purchase of fixed assets ($2.1 million), and distributions to non-controlling interests ($3.3 million).
The Company entered into an interest rate swap effective on June 30, 2022, which will mature on June 30, 2027. It has a $150.0 million notional value adjusted concurrently with scheduled principal payments made on the Company’s term loan. On March 31, 2023, the fair value of the interest rate swap was $3.6 million, a decrease of $1.8 million, net of tax, as compared to December 31, 2022. The fair value of the interest rate swap is included in other assets (current and long term) in the accompanying consolidated balance sheet while the decrease in fair value is presented as unrealized loss in the accompanying consolidated statements of comprehensive income. The interest rate swap arrangement has generated $0.7 million in interest savings since its inception. The average interest rate for the term loan during the 2023 First Quarter was 4.9%.
QUARTERLY DIVIDEND
The Board of Directors declared a quarterly dividend of $0.43 per share payable on June 9, 2023, to shareholders of record on May 18, 2023.
MANAGEMENT REAFFIRMS 2023 EARNINGS GUIDANCE
Management reaffirms that it currently expects the Company’s Adjusted EBITDA for 2023 to be in the range of $75.0 million to $80.0 million. Please note that the earnings guidance represents projected Adjusted EBITDA from existing operations and excludes future acquisitions. The annual guidance figures will not be updated unless there is a material development that causes management to believe that Adjusted EBITDA will be significantly outside the given range.
CONFERENCE CALL INFORMATION
U.S. Physical Therapy's management will host a conference call at 10:30 a.m. ET, 9:30 a.m. CT, on May 4, 2023, to discuss results the Company’s financial results for the quarter ended March 31, 2023. Interested parties may participate in the call by dialing (800) 895-3361 Primary or (785) 424-1062 Alternate and entering reservation number USPHQ123 approximately 10 minutes before the call is scheduled to begin. To listen to the live call, go to the Company's website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. The conference call will be archived and can be accessed until August 4, 2023, at U.S. Physical Therapy’s website.
FORWARD LOOKING STATEMENTS
This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.
GLOSSARY OF TERMS - REVENUE METRICS
Mature clinics are clinics opened or acquired prior to January 1, 2021, and are still operating as of the balance sheet date.
Net rate per patient visit is net patient revenue related to our physical therapy operations divided by total number of patient visits (defined below) during the periods presented.
Patient visits is the number of unique patient visits during the periods presented.
Average visits per day per clinic is patient visits divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of clinics in operation during the periods presented.
ABOUT U.S. PHYSICAL THERAPY, INC.
Founded in 1990, U.S. Physical Therapy, Inc. currently operates 647 outpatient physical therapy clinics in 40 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 35 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention services business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (IN THOUSANDS, EXCEPT PER SHARE DATA)
| |||||||
| Three Months Ended | ||||||
March 31, 2023 |
| March 31, 2022 | |||||
|
| ||||||
Net patient revenue | $ | 126,581 |
| $ | 109,538 |
| |
Other revenue |
| 21,928 |
|
| 22,166 |
| |
Net revenue |
| 148,509 |
|
| 131,704 |
| |
Operating cost: | |||||||
Salaries and related costs |
| 86,040 |
|
| 75,149 |
| |
Rent, supplies, contract labor and other |
| 30,100 |
|
| 28,662 |
| |
Provision for credit losses |
| 1,512 |
|
| 1,305 |
| |
Total operating cost |
| 117,652 |
|
| 105,116 |
| |
Gross profit |
| 30,857 |
|
| 26,588 |
| |
Corporate office costs |
| 13,859 |
|
| 11,556 |
| |
Operating income |
| 16,998 |
|
| 15,032 |
| |
Other income and expense: | |||||||
Relief Funds |
| 467 |
|
| - |
| |
Change in fair value of contingent earn-out consideration |
| (698 | ) |
| - |
| |
Equity in earnings of unconsolidated affiliate |
| 274 |
|
| 339 |
| |
Other and interest income |
| 64 |
|
| 46 |
| |
Change in revaluation of put-right liability |
| (149 | ) |
| 603 |
| |
Interest expense - debt and other, net |
| (2,560 | ) |
| (540 | ) | |
Total other income and expense |
| (2,602 | ) |
| 448 |
| |
Income before taxes |
| 14,396 |
|
| 15,480 |
| |
Provision for income taxes |
| 2,969 |
|
| 3,498 |
| |
Net income |
| 11,427 |
|
| 11,982 |
| |
Less: net loss (income) attributable to non-controlling interest: | |||||||
Redeemable non-controlling interest - temporary equity |
| (2,720 | ) |
| (2,557 | ) | |
Non-controlling interest - permanent equity |
| (1,297 | ) |
| (626 | ) | |
| (4,017 | ) |
| (3,183 | ) | ||
Net income attributable to USPH shareholders | $ | 7,410 |
| $ | 8,799 |
| |
Basic and diluted earnings per share attributable to USPH shareholders | $ | 0.58 |
| $ | 0.67 |
| |
Shares used in computation - basic and diluted |
| 13,024 |
|
| 12,937 |
| |
Dividends declared per common share | $ | 0.43 |
| $ | 0.41 |
|
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (IN THOUSANDS, EXCEPT PER SHARE DATA)
| |||||||
| Three Months Ended | ||||||
March 31, 2023 |
| March 31, 2022 | |||||
|
| ||||||
Net income | $ | 11,427 |
| $ | 11,982 |
| |
Other comprehensive loss | |||||||
Unrealized loss on cash flow hedge |
| (1,817 | ) |
| - |
| |
Tax effect at statutory rate (federal and state) |
| 464 |
|
| - |
| |
Comprehensive income | $ | 10,074 |
| $ | 11,982 |
| |
Comprehensive income attributable to non-controlling interest |
| (4,017 | ) |
| (3,183 | ) | |
Comprehensive income attributable to USPH shareholders | $ | 6,057 |
| $ | 8,799 |
|
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET (IN THOUSANDS, EXCEPT PER SHARE DATA)
| |||||||
| March 31, |
| December 31, | ||||
ASSETS | (unaudited) |
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 32,605 |
|
| $ | 31,594 |
|
Patient accounts receivable, less allowance for credit losses of $2,674 and $2,829, respectively |
| 56,647 |
|
|
| 51,934 |
|
Accounts receivable – other |
| 17,816 |
|
|
| 16,671 |
|
Other current assets |
| 10,726 |
|
|
| 11,067 |
|
Total current assets |
| 117,794 |
|
|
| 111,266 |
|
Fixed assets: |
|
|
| ||||
Furniture and equipment |
| 63,139 |
|
|
| 62,074 |
|
Leasehold improvements |
| 43,525 |
|
|
| 42,877 |
|
Fixed assets, gross |
| 106,664 |
|
|
| 104,951 |
|
Less accumulated depreciation and amortization |
| 82,026 |
|
|
| 80,203 |
|
Fixed assets, net |
| 24,638 |
|
|
| 24,748 |
|
Operating lease right-of-use assets |
| 100,604 |
|
|
| 103,004 |
|
Investment in unconsolidated affiliate |
| 12,160 |
|
|
| 12,131 |
|
Goodwill |
| 501,347 |
|
|
| 494,101 |
|
Other identifiable intangible assets, net |
| 108,991 |
|
|
| 108,755 |
|
Other assets |
| 2,593 |
|
|
| 4,149 |
|
Total assets | $ | 868,127 |
|
| $ | 858,154 |
|
|
|
|
| ||||
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTEREST |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable – trade | $ | 4,233 |
|
| $ | 3,300 |
|
Accounts payable - due to seller of acquired business |
| - |
|
|
| 3,204 |
|
Accrued expenses |
| 45,220 |
|
|
| 37,413 |
|
Current portion of operating lease liabilities |
| 33,650 |
|
|
| 33,709 |
|
Current portion of term loan and notes payable |
| 7,730 |
|
|
| 7,863 |
|
Total current liabilities |
| 90,833 |
|
|
| 85,489 |
|
Notes payable, net of current portion |
| 2,583 |
|
|
| 1,913 |
|
Revolving line of credit |
| 38,000 |
|
|
| 31,000 |
|
Term loan, net of current portion and deferred financing costs |
| 142,098 |
|
|
| 142,918 |
|
Deferred taxes |
| 21,524 |
|
|
| 21,303 |
|
Operating lease liabilities, net of current portion |
| 75,460 |
|
|
| 77,934 |
|
Other long-term liabilities |
| 13,870 |
|
|
| 13,029 |
|
Total liabilities |
| 348,368 |
|
|
| 373,586 |
|
|
|
|
| ||||
Redeemable non-controlling interest - temporary equity |
| 164,283 |
|
|
| 167,515 |
|
|
|
|
| ||||
Commitments and Contingencies |
|
|
| ||||
|
|
|
| ||||
U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: |
|
|
| ||||
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding |
| - |
|
|
| - |
|
Common stock, $.01 par value, 20,000,000 shares authorized, |
|
|
| ||||
15,277,320 and 15,216,326 shares issued, respectively |
| 152 |
|
|
| 152 |
|
Additional paid-in capital |
| 112,123 |
|
|
| 110,317 |
|
Accumulated other comprehensive gain |
| 2,651 |
|
|
| 4,004 |
|
Retained earnings |
| 234,760 |
|
|
| 232,948 |
|
Treasury stock at cost, 2,214,737 shares |
| (31,628 | ) |
|
| (31,628 | ) |
Total USPH shareholders’ equity |
| 318,058 |
|
|
| 315,793 |
|
Non-controlling interest - permanent equity |
| 1,418 |
|
|
| 1,260 |
|
Total USPH shareholders' equity and non-controlling interest - permanent equity |
| 319,476 |
|
|
| 317,053 |
|
Total liabilities, redeemable non-controlling interest, |
|
|
| ||||
USPH shareholders' equity and non-controlling interest - permanent equity | $ | 868,127 |
|
| $ | 858,154 |
|
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS, EXCEPT PER SHARE DATA)
| |||||||
| Three Months Ended | ||||||
| March 31, |
| March 31, | ||||
OPERATING ACTIVITIES |
|
|
| ||||
Net income including non-controlling interest | $ | 11,427 |
|
| $ | 11,982 |
|
Adjustments to reconcile net income including non-controlling interest to |
|
|
| ||||
net cash provided by operating activities: | |||||||
Depreciation and amortization |
| 3,788 |
|
|
| 3,824 |
|
Provision for credit losses |
| 1,512 |
|
|
| 1,305 |
|
Equity-based awards compensation expense |
| 1,806 |
|
|
| 1,846 |
|
Deferred income taxes |
| 221 |
|
|
| 2,132 |
|
Change in revaluation of put-right liability |
| 149 |
|
|
| (603 | ) |
Change in fair value of contingent earn-out consideration |
| 698 |
|
|
| - |
|
Earnings in unconsolidated affiliate |
| (274 | ) |
|
| (339 | ) |
Other |
| 125 |
|
|
| 93 |
|
Changes in operating assets and liabilities: |
|
|
| ||||
Increase in patient accounts receivable |
| (5,999 | ) |
|
| (4,676 | ) |
Increase in accounts receivable – other |
| (796 | ) |
|
| (2,145 | ) |
Increase (decrease) in other assets |
| 1,897 |
|
|
| (735 | ) |
(Decrease) increase in accounts payable and accrued expenses |
| (1,846 | ) |
|
| 1,445 |
|
Decrease in other long-term liabilities |
| (1,359 | ) |
|
| (2,480 | ) |
Net cash provided by operating activities |
| 11,349 |
|
|
| 11,649 |
|
|
|
|
| ||||
INVESTING ACTIVITIES |
|
|
| ||||
Purchase of fixed assets |
| (2,059 | ) |
|
| (2,528 | ) |
Purchase of majority interest in businesses, net of cash acquired |
| (5,796 | ) |
|
| (11,242 | ) |
Purchase of redeemable non-controlling interest, temporary equity |
| (5,178 | ) |
|
| (2,211 | ) |
Purchase of non-controlling interest-permanent |
| - |
|
|
| (99 | ) |
Proceeds on sale of partnership interest - redeemable non-controlling interest |
| 107 |
|
|
| 4 |
|
Distributions from unconsolidated affiliate |
| 245 |
|
|
| 132 |
|
Net cash used in investing activities |
| (12,681 | ) |
|
| (15,944 | ) |
|
|
|
| ||||
FINANCING ACTIVITIES |
|
|
| ||||
Distributions to non-controlling interest, permanent and temporary equity |
| (3,297 | ) |
|
| (3,711 | ) |
Proceeds from revolving line of credit |
| 7,000 |
|
|
| 35,000 |
|
Proceeds from term loan |
| - |
|
|
| (31,000 | ) |
Payments on term loan |
| (938 | ) |
|
| - |
|
Principal payments on notes payable |
| (422 | ) |
|
| (332 | ) |
Net cash provided by (used in) financing activities |
| 2,343 |
|
|
| (43 | ) |
|
|
|
| ||||
Net decrease in cash and cash equivalents |
| 1,011 |
|
|
| (4,338 | ) |
Cash and cash equivalents - beginning of period |
| 31,594 |
|
|
| 28,567 |
|
Cash and cash equivalents - end of period | $ | 32,605 |
|
| $ | 24,229 |
|
|
|
|
| ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |
|
|
| ||||
Cash paid during the period for: |
|
|
| ||||
Income taxes | $ | 442 |
|
| $ | 81 |
|
Interest paid |
| 1,377 |
|
|
| 525 |
|
Non-cash investing and financing transactions during the period: |
|
|
| ||||
Purchase of businesses - seller financing portion |
| 360 |
|
|
| 300 |
|
Notes payable related to purchase of redeemable non-controlling interest, temporary equity |
| 611 |
|
|
| 246 |
|
Notes payable related to purchase of non-controlling interest, permanent equity |
| - |
|
|
| 296 |
|
Notes receivable related to sale of partnership interest - redeemable non-controlling interest |
| 532 |
|
|
| - |
|
Dividends payable to USPH shareholders | $ | 5,617 |
|
| $ | 5,327 |
|
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
OPERATING RESULTS AND ADJUSTED EBITDA
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
The following tables provide details of the diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Operating Results and Adjusted EBITDA. Management believes providing Operating Results and Adjusted EBITDA to investors is useful information for comparing the Company's period-to-period results.
Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, Relief Funds, changes in revaluation of put-right liability, equity-based awards compensation expense, and related portions for non-controlling interests. Management believes reporting Adjusted EBITDA is useful information for investors in comparing the Company’s period-to-period results as well as comparing with similar businesses which report adjusted EBITDA as defined by their company.
Operating Results, a non-GAAP measure, equals net income attributable to USPH diluted shareholders per the consolidated statements of income, less a change in revaluation of the put-right liability, Relief Funds, changes in fair value of contingent earn-out consideration, and any allocations to non-controlling interests, all net of taxes. Operating Results per diluted share also exclude the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.
Management uses Operating Results and Adjusted EBITDA, which eliminates certain items described above that can be subject to volatility and unusual costs, as one the principal measures to evaluate and monitor financial performance period over period. Management believes that presenting Operating Results and Adjusted EBITDA is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures.
Operating Results and Adjusted EBITDA are not measures of financial performance under GAAP. Adjusted EBITDA and Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES OPERATING RESULTS AND ADJUSTED EBITDA 2023 PERIODS COMPARED TO 2022 PERIODS (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited)
| |||||||
| Three Months Ended March 31, | ||||||
|
| 2023 |
|
|
| 2022 (1) |
|
Adjusted EBITDA |
|
|
| ||||
Net income attributable to USPH shareholders | $ | 7,410 |
| $ | 8,799 |
| |
Adjustments: | |||||||
Depreciation and amortization |
| 3,788 |
|
| 3,824 |
| |
Change in fair value of contingent earn-out consideration |
| 698 |
|
|
| - |
|
Interest income |
| (64 | ) |
| (46 | ) | |
Relief funds |
| (467 | ) |
| - |
| |
Change in revaluation of put-right liability |
| 149 |
|
| (603 | ) | |
Interest expense - debt and other, net |
| 2,560 |
|
| 540 |
| |
Provision for income taxes |
| 2,969 |
|
| 3,498 |
| |
Equity-based awards compensation expense |
| 1,806 |
|
| 1,846 |
| |
Allocation to non-controlling interests |
| (371 | ) |
| (363 | ) | |
Adjusted EBITDA (a non-GAAP measure) |
| 18,478 |
|
| 17,495 |
| |
|
|
|
| ||||
Earnings per share |
|
|
| ||||
Computation of earnings per share - USPH shareholders: |
|
| |||||
Net income attributable to USPH shareholders | $ | 7,410 |
| $ | 8,799 |
| |
Charges to retained earnings: | |||||||
Revaluation of redeemable non-controlling interest |
| 119 |
|
| (153 | ) | |
Tax effect at statutory rate (federal and state) |
| (30 | ) |
| 39 |
| |
$ | 7,499 |
| $ | 8,685 |
| ||
Earnings per share (basic and diluted) | $ | 0.58 |
| $ | 0.67 |
| |
|
|
|
| ||||
| |||||||
Operating Results |
|
|
| ||||
Net income attributable to USPH shareholders | $ | 7,410 |
|
| $ | 8,799 |
|
Adjustments: | |||||||
Change in fair value of contingent earn-out consideration |
| 698 |
|
|
| - |
|
Change in revaluation of put-right liability |
| 149 |
|
| (603 | ) | |
Allocation to non-controlling interests |
| 33 |
|
| - |
| |
Relief Funds |
| (467 | ) |
| - |
| |
Tax effect at statutory rate (federal and state) |
| (105 | ) |
| 154 |
| |
Operating Results (a non-GAAP measure) | $ | 7,718 |
| $ | 8,350 |
| |
Basic and diluted Operating Results per share (a non-GAAP measure) | $ | 0.59 |
| $ | 0.65 |
| |
Shares used in computation - basic and diluted |
| 13,025 |
|
| 12,937 |
|
(1) | Revised to conform to current year presentation. |
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES REVENUE METRICS
| |||||||||||||||||||||||||
| Number of Clinics |
| Net Rate Per Patient Visit (1) |
| Patient Visits (1) |
| Average Visits Per Day Per Clinic (1) | ||||||||||||||||||
2023 |
| 2022 |
| 2023 |
| 2022 |
| 2023 |
| 2022 |
| 2023 |
| 2022 | |||||||||||
First quarter | 647 | 601 | $ | 103.12 | $ | 103.00 | 1,227,490 | 1,063,519 | 29.8 | 27.9 | |||||||||||||||
Second quarter | 608 |
| $ | 103.18 |
| 1,145,554 |
| 29.5 |
| ||||||||||||||||
Third quarter | 614 |
| $ | 104.01 |
| 1,122,070 |
| 28.8 |
| ||||||||||||||||
Fourth quarter | 640 |
| $ | 104.28 |
| 1,152,139 |
| 29.1 |
| ||||||||||||||||
(1) | See definition of the metrics above in the Glossary of Terms – Revenue Metrics on page 6. |
Last Trade: | US$84.56 |
Daily Change: | -2.22 -2.56 |
Daily Volume: | 47,291 |
Market Cap: | US$1.280B |
September 03, 2024 August 21, 2024 August 13, 2024 July 03, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB